Advertisement

Advances in Therapy

, Volume 36, Issue 11, pp 3265–3278 | Cite as

Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study

  • Richard Ofori-AsensoEmail author
  • Danny Liew
  • Samanta Lalic
  • Mohsen Mazidi
  • Dianna J. Magliano
  • Zanfina Ademi
  • J. Simon Bell
  • Jenni Ilomaki
Original Research

Abstract

Introduction

Non-adherence and non-persistence to diabetes medications are associated with worse clinical outcomes. In this study, we aimed to characterise the 1-year switching, adherence, and persistence patterns among people with diabetes aged 18 years and older prescribed sodium-glucose co-transporter 2 inhibitors (SGLT2is) in Australia.

Methods

Using data from Australia’s national Pharmaceutical Benefits Scheme (PBS), we identified 11,981 adults (mean age 60.9 years; 40.5% female) newly initiated on SGLT2is (5993 dapagliflozin; 5988 empagliflozin) from September 2015 to August 2017. Adherence was assessed via the proportion of days covered (PDC), persistence was defined as the continuous use of SGLT2i without a gap of ≥ 90 days, and switching was defined as the first change from dapagliflozin to empagliflozin or vice versa. Generalised linear models (GLMs) were used to compare the adherence (PDC = continuous), logistic regression models were used to compare the likelihoods of being adherent (PDC ≥ 0.80), and Cox proportional hazard models were used to compare the likelihoods of persistence and switching between people prescribed empagliflozin and dapagliflozin.

Results

Overall, 65.8% (7879/11,981) of people dispensed SGLT2is were adherent (PDC ≥ 0.80) and 72.1% (8644/11,981) were persistent at 12 months. The mean PDC was 0.79 ± 0.27. The use of empagliflozin was associated with higher adherence (PDC = continuous) [odds ratio (OR) 1.04, 95% confidence interval (CI) 1.03–1.05], being adherent (OR 1.39, 95% CI 1.29–1.51), and persisting for 12 months [hazard ratio (HR) 1.14, 95% CI 1.06–1.22] compared with dapagliflozin. Only 4.3% (509/11,981) of people switched between the SGLT2i. Compared with dapagliflozin, people initiated on empagliflozin were less likely to switch [HR 0.46, 95% CI 0.38–0.55].

Conclusions

A considerable proportion of Australians prescribed SGLT2is were non-adherent or non-persistent. However, empagliflozin was associated with better adherence and persistence rates and a lower likelihood of switching compared with dapagliflozin.

Keywords

Adherence Australia Diabetes Persistence SGLT2 inhibitors Switching 

Notes

Acknowledgements

The authors are grateful to the Australian Government Department of Human Services for providing the Pharmaceutical Benefits Scheme (PBS) data set that was used in this study.

Funding

No funding or sponsorship was received for this study or publication of this article.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Danny Liew reports past participation in advisory boards and/or receiving honoraria from Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi, and Shire for work unrelated to this study. Dianna J. Magliano reports past participation in advisory boards and/or receiving honoraria from AstraZeneca and Bayer for work unrelated to this study. Richard Ofori-Asenso is now also affilitated with Copenhagen Centre for Regulatory Science (CORS), Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Samanta Lalic, Mohsen Mazidi, Zanfina Ademi, J. Simon Bell and Jenni Ilomaki have nothing to disclose.

Compliance with Ethics Guidelines

This article does not contain any new studies with human or animal subjects performed by any of the authors; as such, informed consent of individuals was not required. The study was approved by the Monash University Human research Ethics Committee and the analysis plan was noted by the Australian Government Department of Human Services.

Data Availability

The data used for the analysis can be obtained by direct application to the Australian Government department of Health.

Supplementary material

12325_2019_1077_MOESM1_ESM.docx (37 kb)
Supplementary material 1 (DOCX 37 kb)

References

  1. 1.
    Zimmet PZ. Diabetes and its drivers: the largest epidemic in human history? Clin Diabetes Endocrinol. 2017;3:1.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Diabetes facts & figures. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Accessed 5 May 2019
  3. 3.
  4. 4.
    Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab. 2016;20(4):546–51.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Fowler M. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.CrossRefGoogle Scholar
  6. 6.
    Federal election 2013: a national diabetes strategy and action plan. https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/e549bdb8-0f80-46f8-b827-35cb4f1b6cd2.pdf. Accessed 10 May 2019
  7. 7.
    Lee CM, Colagiuri R, Magliano DJ, Cameron AJ, Shaw J, Zimmet P, Colagiuri S. The cost of diabetes in adults in Australia. Diabetes Res Clin Pract. 2013;99(3):385–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:95–104.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Lachin JM, Orchard TJ, Nathan DM, Group DER. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):39–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Whaley-Connell A, Sowers JR. Implications for glucose measures in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes. 2014;63(1):45–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Marathe PH, Gao HX, Close KL. American Diabetes Association standards of medical care in diabetes 2017. J Diabetes. 2017;9(4):320–4.PubMedCrossRefGoogle Scholar
  12. 12.
    American Diabetes A. Standards of medical care in diabetes—2019 abridged for primary care providers. Clin Diabetes. 2019;37(1):11–34.CrossRefGoogle Scholar
  13. 13.
    Raval AD, Vyas A. National trends in diabetes medication use in the United States: 2008 to 2015. J Pharm Pract. 2018.  https://doi.org/10.1177/0897190018815048 CrossRefPubMedGoogle Scholar
  14. 14.
    Mann DM, Woodward M, Ye F, Krousel-Wood M, Muntner P. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med. 2009;169(18):1718–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015;32(6):725–37.PubMedCrossRefGoogle Scholar
  17. 17.
    McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(4):1040–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19(7):31–41.PubMedGoogle Scholar
  20. 20.
    Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, Zhao Y, Mauldin PD. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35(12):2533–9.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, Wang BH, Liew D. Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc Res. 2019;115(2):266–76.PubMedCrossRefGoogle Scholar
  23. 23.
    Peene B, Benhalima K. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5(5):124–36.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Pioli MR, Ritter AMV, Modolo R. Unsweetening the heart: possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects. Am J Hypertens. 2018;31(3):274–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRefGoogle Scholar
  26. 26.
    Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jorgensen ME, Thuresson M, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136(3):249–59.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628–39.PubMedCrossRefGoogle Scholar
  28. 28.
    Invoka (Canagliflozin) removal from the pharmaceutical benefits scheme on 1 August 2015. https://www.endocrinesociety.org.au/documents/INVOKANADHCPLFeb16removalPBS.pdf. Accessed 12 May 2019
  29. 29.
    A new blood glucose management algorithm for type 2 diabetes A position statement of the Australian Diabetes Society. https://diabetessociety.com.au/documents/ADSPOSITIONSTATEMENTv2.12016Uploadedtowebsite.pdf. Accessed 15 May 2019
  30. 30.
  31. 31.
    Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, Segrave A, Pearson SA. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8:634.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Ofori-Asenso R, Ilomaki J, Tacey M, Zomer E, Curtis AJ, Bell JS, Zoungas S, Liew D. Patterns of statin use and long-term adherence and persistence among older adults with diabetes. J Diabetes. 2018;10(9):699–707.PubMedCrossRefGoogle Scholar
  33. 33.
    Ofori-Asenso R, Ilomaki J, Tacey M, Si S, Curtis AJ, Zomer E, Bell JS, Zoungas S, Liew D. Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. Br J Clin Pharmacol. 2019;85(1):227–35.PubMedCrossRefGoogle Scholar
  34. 34.
    Ofori-Asenso R, Ilomaki J, Zomer E, Curtis AJ, Zoungas S, Liew D. A 10-year trend in statin use among older adults in Australia: an analysis using national pharmacy claims data. Cardiovasc Drugs Ther. 2018;32(3):265–72.PubMedCrossRefGoogle Scholar
  35. 35.
    Ofori-Asenso R, Ilomaki J, Tacey M, Zomer E, Curtis AJ, Si S, Zullo AR, Korhonen MJ, Bell JS, Zoungas S, et al. Switching, discontinuation, and reinitiation of statins among older adults. J Am Coll Cardiol. 2018;72(21):2675–7.PubMedCrossRefGoogle Scholar
  36. 36.
    McGovern A, Hinton W, Calderara S, Munro N, Whyte M, de Lusignan S. A class comparison of medication persistence in people with type 2 diabetes: a retrospective observational study. Diabetes Ther. 2018;9(1):229–42.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Rascati KL, Worley K, Meah Y, Everhart D. Adherence, persistence, and health care costs for patients receiving dipeptidyl peptidase-4 inhibitors. J Manag Care Spec Pharm. 2017;23(3):299–306.PubMedGoogle Scholar
  38. 38.
    Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009;12(6):989–95.PubMedCrossRefGoogle Scholar
  39. 39.
    Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–10.PubMedCrossRefGoogle Scholar
  41. 41.
    Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther. 2014;31(12):1287–305.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Ofori-Asenso R, Ilomaki J, Tacey M, Zomer E, Curtis AJ, Bell JS, Zoungas S, Liew D. Predictors of statin use among older adults: a nationwide cross-sectional study. J Clin Lipidol. 2019;13(1):156–62 (e151).PubMedCrossRefGoogle Scholar
  44. 44.
    Vaduganathan M, Sathiyakumar V, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, Butler J, Cannon CP, Bhatt DL. Prescriber patterns of SGLT2i after expansions of U S Food and Drug Administration labeling. J Am Coll Cardiol. 2018;72(25):3370–2.PubMedCrossRefGoogle Scholar
  45. 45.
    Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):e009417.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci. 2016;130(3):159–69.PubMedCrossRefGoogle Scholar
  47. 47.
    Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–307.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279–84.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Cai J, Divino V, Burudpakdee C. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States. Curr Med Res Opin. 2017;33(7):1317–28.PubMedCrossRefGoogle Scholar
  52. 52.
    Cai J, Wang Y, Baser O, Xie L, Chow W. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. J Med Econ. 2016;19(12):1175–86.PubMedCrossRefGoogle Scholar
  53. 53.
    Bell KF, Cappell K, Liang M, Kong AM. Comparing medication adherence and persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or sulfonylureas. Am Health Drug Benefits. 2017;10(4):165–74.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Nishimura R, Kato H, Kisanuki K, Oh A, Hiroi S, Onishi Y, Guelfucci F, Shimasaki Y. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open. 2019;9(3):e025806.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Jermendy G, Rokszin G, Abonyi-Tóth Z, Wittmann I, Kempler P. Persistence to treatment with novel antidiabetic drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in people with type 2 diabetes: a nationwide cohort study. Diabetes Ther. 2018;9(5):2133–2141.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Sharkey N, Maxwell P. Will Sglt2 inhibitors prove to be a ‘multiple’ gamechanger? Ulster Med J. 2019;88(1):8–9.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Kumana CR, Tan KCB, Cheung BMY. Absolute benefits of empagliflozin in type 2 diabetes: a game changer? Postgrad Med J. 2017;93(1101):373–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Vervloet M, van Dijk L, de Bakker DH, Souverein PC, Santen-Reestman J, van Vlijmen B, van Aarle MC, van der Hoek LS, Bouvy ML. Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with Type 2 diabetes: evidence from a randomized controlled trial. Diabet Med. 2014;31(7):821–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Shrank WH. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22.PubMedGoogle Scholar
  60. 60.
    Lindenmeyer A, Hearnshaw H, Vermeire E, Van Royen P, Wens J, Biot Y. Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. J Clin Pharm Ther. 2006;31(5):409–19.PubMedCrossRefGoogle Scholar
  61. 61.
    Schoenthaler A, Cuffee Y. A systematic review of interventions to improve adherence to diabetes medications within the patient-practitioner interaction. J Clin Outcomes Manag. 2013;20(11):494–506.Google Scholar
  62. 62.
    Sapkota S, Brien JA, Greenfield J, Aslani P. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes—impact on adherence. PLoS One. 2015;10(2):e0118296.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Williams JL, Walker RJ, Smalls BL, Campbell JA, Egede LE. Effective interventions to improve medication adherence in type 2 diabetes: a systematic review. Diabetes Manag. 2014;4(1):29–48.CrossRefGoogle Scholar
  64. 64.
    Si S, Ofori-Asenso R, Briffa T, Sanfilippo FM, Ilomaki J, Qin X, Tacey M, Reid CM, Liew D. Long-term persistence and adherence to blood pressure lowering agents among older Australians. Pharmacoepidemiol Drug Saf. 2019;28(6):788–95.PubMedCrossRefGoogle Scholar
  65. 65.
    Si S, Ofori-Asenso R, Briffa T, Ilomaki J, Sanfilippo F, Reid CM, Liew D. Dispensing patterns of blood pressure lowering agents in older Australians from 2006 to 2016. J Cardiovasc Pharmacol Ther. 2019;24(3):242–50.PubMedCrossRefGoogle Scholar
  66. 66.
    Li X, Cole SR, Westreich D, Brookhart MA. Primary non-adherence and the new-user design. Pharmacoepidemiol Drug Saf. 2018;27(4):361–4.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295–311.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Epidemiology and Preventive MedicineMonash UniversityMelbourneAustralia
  2. 2.Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical SciencesMonash UniversityMelbourneAustralia
  3. 3.Division of Food and Nutrition Science, Department of Biology and Biological EngineeringChalmers University of TechnologyGothenburgSweden
  4. 4.Baker Heart and Diabetes InstituteMelbourneAustralia
  5. 5.School of Pharmacy and Medical SciencesUniversity of South AustraliaAdelaideAustralia

Personalised recommendations